News from neuralstem, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jul 23, 2015, 07:45 ET
Neuralstem Logo.

US District Court Rules In Favor Of Neuralstem In Patent Infringement Case

 Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy...

Jun 29, 2015, 09:22 ET
Neuralstem Logo.

Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market

 Neuralstem, Inc. (NYSE MKT: CUR), a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy...

Jun 26, 2015, 07:32 ET
Neuralstem Logo.

Preclinical Data On Neuralstem's Genetically Modified HK532-IGF-1 Stem Cells In Alzheimer's Disease Presented At International Society For Stem Cell Research Annual Meeting

Neuralstem, Inc. (NYSE MKT: CUR), a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy...

May 08, 2015, 07:30 ET
NEURALSTEM, INC. LOGO

Neuralstem Reports First Quarter 2015 Financial Results And Provides Business and Clinical Update

 Neuralstem, Inc. (NYSE MKT: CUR) a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy...

May 06, 2015, 07:31 ET
Neuralstem Logo.

Neuralstem Appoints Jonathan Lloyd Jones as Chief Financial Officer

Neuralstem, Inc. (NYSE MKT: CUR), a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy...

Mar 16, 2015, 07:30 ET
Neuralstem Logo.

Neuralstem Reports Fiscal 2014 Fourth Quarter Financial And Year-End Business Results

Neuralstem, Inc. (NYSE MKT: CUR) (the "Company" or "Neuralstem") today reported its financial results for the fourth quarter and year ended...

Mar 12, 2015, 06:50 ET
Neuralstem Logo.

Neuralstem Announces Topline Results Of Phase II ALS Trial

 Neuralstem, Inc. (NYSE MKT: CUR) announced top line data from the Phase II trial of NSI-566 spinal cord-derived neural stem cells under...

Mar 04, 2015, 16:31 ET
Neuralstem Logo.

Neuralstem To Present At Barclays Global Healthcare Conference 2015

 Neuralstem, Inc. (NYSE MKT: CUR) announced that Richard Garr, President and CEO, will present at the Barclays Global Healthcare Conference...

Feb 03, 2015, 09:03 ET
Neuralstem Logo

Neuralstem to Present at BIO CEO & Investor Conference 2015

 Neuralstem, Inc. (NYSE MKT: CUR) announced that Richard Garr, President and CEO, will present at the 17th Annual BIO CEO & Investor...

Jan 06, 2015, 09:03 ET
Neuralstem Logo.

Neuralstem To Present At Biotech Showcase 2015

 Neuralstem, Inc. (NYSE MKT: CUR) announced that the Company will present at the seventh annual Biotech Showcase in San Francisco on Tuesday,...

Nov 17, 2014, 09:02 ET
Neuralstem Logo.

Neuralstem NSI-189 Phase Ib Major Depression Disorder Neurogenic Biomarker Data Presented At The CNS Summit

 Neuralstem, Inc. (NYSE MKT: CUR) announced that blood-based biomarkers for major depressive disorder (MDD) identified a rapid...

Nov 10, 2014, 09:00 ET
Neuralstem Logo

Neuralstem Announces Publication Of Long Term Cell Survival From Phase I NSI-566 ALS Study In The Journal "Annals Of Clinical And Translational Neurology"

Neuralstem, Inc. (NYSE MKT: CUR) announced the publication of results evaluating long term cell survival and differentiation of NSI-566...

Nov 07, 2014, 09:00 ET
Neuralstem Logo

Neuralstem Reports Third Quarter Financial Results And Provides Business And Clinical Update

 Neuralstem, Inc. (NYSE MKT: CUR) today reported its financial results for the three months and nine months ended September 30, 2014 and...

Oct 23, 2014, 09:15 ET
Neuralstem Logo.

Neuralstem Alzheimer's Disease Animal Data Presented At The Congress Of Neurological Surgeons Annual Meeting

Neuralstem, Inc. (NYSE MKT: CUR) announced that the first data in a study transplanting its neural stem cells in an animal model of...

Oct 09, 2014, 09:15 ET
Neuralstem Logo. (PRNewsFoto/NEURALSTEM, INC.)

First Patient Treated In Neuralstem Phase I Spinal Cord Injury Stem Cell Trial Through The UC San Diego Sanford Stem Cell Clinical Center

 Neuralstem, Inc. (NYSE MKT: CUR) announced that the first patient was treated last week in the Phase I trial testing NSI-566 human neural...

Sep 22, 2014, 09:15 ET
Neuralstem Logo. (PRNewsFoto/NEURALSTEM, INC.)

Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data

 Neuralstem, Inc. (NYSE MKT: CUR) announced that Jonathan D. Glass, MD, site investigator at Emory University, presented long-term follow up...

Sep 05, 2014, 09:15 ET
Neuralstem Logo. (PRNewsFoto/NEURALSTEM, INC.)

Neuralstem President And CEO To Present At The 2014 Rodman & Renshaw Annual Global Investment Conference

Neuralstem, Inc. (NYSE MKT: CUR) announced that President and CEO Richard Garr will present at the 16th Annual Rodman & Renshaw Global...

Aug 08, 2014, 08:00 ET
Neuralstem Logo. (PRNewsFoto/NEURALSTEM, INC.)

Neuralstem Reports Second Quarter Financial Results And Provides Business And Clinical Update

 Neuralstem, Inc. (NYSE MKT: CUR) today reported its financial results for the three months and six months ended June 30, 2014 and provided a...

Aug 04, 2014, 09:15 ET
Neuralstem Logo. (PRNewsFoto/NEURALSTEM, INC.)

Final Patient Treated In Neuralstem Phase II ALS Stem Cell Trial

 Neuralstem, Inc. (NYSE MKT: CUR) announced that the final patient was treated in its Phase II trial using NSI-566 spinal cord-derived neural...

Jun 30, 2014, 09:15 ET

Neuralstem Added To Russell 3000 Index

 Neuralstem, Inc. (NYSE MKT: CUR) reports that its shares have been added to the broad-market Russell 3000® Index. Annual...